Cardiorenal Safety and Efficacy of Sotagliflozin: A Stratified Meta‐Analysis by Diabetes Type and Dosage
Pooled result · Expanded CV composite endpointResult — go to the resultRelative risk 0.80 95% CI 0.75–0.88Authors' conclusion
Sotagliflozin provides significant and consistent cardiovascular benefit in patients with diabetes, particularly type 2 diabetes, with good safety. A potential renal protective trend exists.
Study context
- Population
- Patients with diabetes in RCTs of sotagliflozin11 RCT datasets
- Comparison
- Sotagliflozin vs control
- Outcome
- Expanded MACE and HF composite: CV death, HF hospitalisation, non-fatal MI, non-fatal stroke
Methodological detailssubgroup, sensitivity and cumulative analyses, Cochrane RoB 2.0
- Subgroup, sensitivity and cumulative analyses
- Cochrane RoB 2.0
Pooled result
Expanded CV composite endpoint
Relative risk
0.80
95% CI 0.75–0.88
P < 0.01
Sotagliflozinvs Control
RR 0.80 (95% CI 0.75–0.88); P < 0.01
As reported in the abstract
Further pooled results
| Outcome | RR (95% CI) | P value | |
|---|---|---|---|
| Substantial decline in renal functionSotagliflozinvs ControlNot statistically significant | 0.77 (0.46–1.27) | P = 0.53 | |
| 0.512Relative risk (log scale) |
Subgroups: CV benefit
- Highly consistent CV benefit in T2D, in studies with flexible dose titration (200 → 400 mg), and across follow-up periods
Original publication
Cardiorenal Safety and Efficacy of Sotagliflozin: A Stratified Meta‐Analysis by Diabetes Type and Dosage. Diabetes Obes Metab. Published 1 June 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →